top of page

Our growing portfolio...

Cerus Endovascular Ltd., a privately held medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiological devices and delivery systems to treat acute, life-threatening intracranial aneurysms, and it has been granted U.S. Patent No. 10,130,372. 


The U.S. patent covers the unique construction of two of the Company's lead devices, Contour Neurovascular System™ and NEQSTENT™.

The Company's patent portfolio includes global filings pursuing a corresponding scope of patent protection. With the issuance of this key patent, the Company has five issued US patents to date and over 20+ pending patent applications worldwide.


"We are pleased to add to our growing portfolio of intellectual property," said Cerus Endovascular President Stephen Griffin, PhD. "We have developed a portfolio of novel, high value-added and clinically differentiated aneurysm treatment technologies that have formed a platform to address the insufficiently met clinical needs of today's $1 billion, and growing, intracranial aneurysm market."

"In developing our platform, we have identified some of the shortcomings of existing technologies. Not too long ago, coiling was a major evolution, but technology has progressed. Today, instead of putting 7-10 coils in an aneurysm, we are looking at much faster treatments that equate to better success rates. We recognized the need for advancement in this field, and we believe our technology is going to be the next evolutionary step," concluded Dr. Griffin.

Contour Neurovascular System™ and NEQSTENT™ are revolutionary low-profile implantable devices for deployment across the neck of an aneurysm. The unique shape and features of the devices allow physicians to treat a range of aneurysm morphologies, including wide-neck and/or bifurcation aneurysms. 

bottom of page